Avadel pharmaceuticals reports second quarter 2025 financial results and raises 2025 revenue guidance

-- generated lumryz™ net revenue of $68.1 million, a 64% increase compared to second quarter 2024, net income of $9.7 million and earnings per share of $0.10 -- -- 3,100 patients on lumryz as of june 30, 2025, a 63% increase compared to june 30, 2024 -- -- raises 2025 full year revenue guidance to $265 - $275 million -- -- received orphan drug designation from fda for lumryz™ (sodium oxybate) for extended-release oral suspension for the treatment of idiopathic hypersomnia (ih) --         -- on track to complete enrollment in pivotal phase 3 revitalyz™ study evaluating efficacy and safety of lumryz in ih by end of 2025 -- -- avadel management to host conference call today at 8:30 a.m. et -- dublin, ireland, aug. 07, 2025 (globe newswire) -- avadel pharmaceuticals plc (nasdaq: avdl), a biopharmaceutical company focused on transforming medicines to transform lives, today increased its revenue guidance for the year as it announced its financial results for the second quarter ended june 30, 2025.
AVDL Ratings Summary
AVDL Quant Ranking